Loading
If a lipid nanoparticle can make CAR-T cells inside the body for lymphoma, it could be redosed weekly against solid-tumour targets that autologous CAR-T cannot sustain.
If a lipid nanoparticle can make CAR-T cells inside the body for lymphoma, this idea redoses it weekly against Claudin 18.2 and Glypican-3 in gastric, liver and pancreatic cancer. Solid-tumour CAR-T fails partly through exhaustion and poor persistence of a single infused product, whereas transient, redosable in vivo CAR expression could deliver repeated waves of fresh effector cells, limit off-tumour toxicity, avoid lymphodepletion and remove manufacturing delay. The test is a phase 1 in CLDN18.2-positive gastric cancer after the satricabtagene autoleucel proof of concept, measuring CAR-positive T-cell frequency, tumour infiltration and toxicity per dose. Speculative in maturity, it addresses the bottleneck Manufacturing cost and time for living and radioactive medicines.
One of the most cited reviews Europe PMC returns for GPC3 in Gastric & gastro-oesophageal junction cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for CLDN18 in Gastric & gastro-oesophageal junction cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One technology page and one idea page on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One of the most cited trial reports Europe PMC returns for GPC3 in Hepatocellular carcinoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares Glypican-3, Satricabtagene autoleucel, Claudin 18.2, CAR-T cell therapy.
Shares In vivo CAR-T manufactured and priced like a generic biologic, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma, In vivo CAR-T, Manufacturing cost and time for living and radioactive medicines.
Shares In vivo CAR-T manufactured and priced like a generic biologic, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma, In vivo CAR-T, Manufacturing cost and time for living and radioactive medicines.
Shares Glypican-3, Satricabtagene autoleucel, In vivo CAR-T, Claudin 18.2.
Shares In vivo CAR-T manufactured and priced like a generic biologic, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma, In vivo CAR-T, Manufacturing cost and time for living and radioactive medicines.
Shares Satricabtagene autoleucel, Claudin 18.2, CAR-T cell therapy, Gastric & gastro-oesophageal junction cancer.
Shares Satricabtagene autoleucel, Claudin 18.2, CAR-T cell therapy, Gastric & gastro-oesophageal junction cancer.
Shares Satricabtagene autoleucel, CAR-T cell therapy, Hepatocellular carcinoma, Gastric & gastro-oesophageal junction cancer.